MedTrace Logo

MRI Scan and Intra-labyrinthine Schwannoma

NCT03580850 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-07-13

No results posted yet for this study

Summary

Evaluate the interest of gadolinium for the positive and topographic diagnosis of intra-labyrinthine schwannoma, comparing T1 sequence acquired after gadolinium injection to a sequence of fast imaging type employing steady state acquisition (FIESTA-C)

Conditions

  • Schwannoma

Interventions

OTHER

No intervention in this restrospective study

This study is an obervational study

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Principal Investigators

  • Francis VEILLON, MD, PhD · University Hospital, Strasbourg, France

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-02
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03580850 on ClinicalTrials.gov